IM1305

Search documents
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
Globenewswire· 2025-10-20 20:00
REHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that on October 16, 2025, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq ...
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
Globenewswire· 2025-09-10 12:00
Core Viewpoint - Purple Biotech Ltd. is advancing its clinical-stage therapies, particularly NT219, which targets tumor immune evasion and drug resistance, and has received an intention to grant a European Patent for its combination therapies [1][2][3] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes NT219, CAPTN-3, and CM24 [4] - The company is headquartered in Rehovot, Israel, and is publicly traded on NASDAQ and TASE under the ticker PPBT [4] Patent and Intellectual Property - The European Patent Office intends to grant a patent for NT219 combinations with leading immunotherapies, which could provide broad protection until 2036 [2] - The patent covers combinations of NT219 with various immunotherapies and chemotherapies, aimed at enhancing treatment sensitivity for resistant tumors [2] Clinical Development - A Phase 2 study for NT219 in combination with immunotherapy is underway, specifically targeting squamous cell carcinoma of the head and neck [3][5] - The study evaluates NT219 with pembrolizumab and cetuximab, building on previous Phase 1 results that showed anti-tumor activity [3][5] - Preclinical data supports the synergistic effects of NT219 with immunotherapy, indicating a shift in the tumor microenvironment from immunosuppressive to immunoreactive [3] Therapeutic Mechanism - NT219 functions as a dual inhibitor targeting IRS1/2 and STAT3, both of which are critical in drug resistance and tumor immune evasion [3][5] - The company is also developing CAPTN-3, a platform of tri-specific antibodies designed to enhance immune response within the tumor microenvironment [4]
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
Globenewswire· 2025-09-03 11:00
Core Insights - Purple Biotech is advancing the development of a tri-specific antibody targeting TROP2, which is part of its CAPTN-3 platform aimed at overcoming tumor immune evasion and drug resistance [1][2][8] - The company plans to submit an Investigational New Drug (IND) application for its first CAPTN-3 tri-specific antibody, IM1240, in 2026 [1] - Encouraging preclinical results have shown sustained tumor regression in human triple negative breast cancer (TNBC) models, with significant cell death in various tumor types at low doses [4][5] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance [8] - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [8][9] - The CAPTN-3 platform utilizes a unique mechanism of action that engages both innate and adaptive immune systems to enhance anti-tumoral responses [8] Technology and Mechanism - The tri-specific antibody IM1305 includes a masked anti-CD3 arm designed to reduce off-target effects while enhancing efficacy in the tumor microenvironment [3][6] - TROP2 is expressed in various solid tumors and is linked to poor prognosis, making it a significant target for therapeutic development [5][6] - The CAPTN-3 platform's ability to recruit multiple immune effectors (T and NK cells) is expected to provide a strong rationale for its effectiveness across diverse tumor types [6][7] Future Prospects - The company is optimistic about the growing interest in TROP2 as a therapeutic target and aims to leverage its technological advancements to accelerate development timelines [7] - Purple Biotech believes that its CAPTN-3 platform can generate multiple programs and expand partnership opportunities in the oncology space [7]